TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Zivo Bioscience ( (ZIVO) ) is now available.
At the annual meeting of shareholders held on June 9, 2025, Zivo Bioscience, Inc. announced the election of two Class III directors to its Board of Directors for a three-year term, the ratification of BDO USA, P.C. as its independent registered public accounting firm for the fiscal year ending December 31, 2025, and the approval of executive compensation on an advisory basis. With approximately 66.11% of the company’s common stock represented, all proposals were approved by the shareholders, indicating strong support for the company’s governance and financial strategies.
Spark’s Take on ZIVO Stock
According to Spark, TipRanks’ AI Analyst, ZIVO is a Underperform.
Zivo Bioscience faces significant financial challenges, including negative equity and cash flow issues, which are the primary factors in its low score. Despite some technical indicators showing neutrality, the company’s negative valuation metrics further impact the score. Urgent financial restructuring is necessary for sustainability.
To see Spark’s full report on ZIVO stock, click here.
More about Zivo Bioscience
Average Trading Volume: 882
Technical Sentiment Signal: Sell
Current Market Cap: $47.63M
For detailed information about ZIVO stock, go to TipRanks’ Stock Analysis page.